Imunon, Inc.

IMNN is the ticker symbol for Imunon, Inc., a publicly traded US company.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

Key metrics include a return on equity of -126.5%, a debt-to-equity ratio of 1.39.

The company reports trailing twelve-month revenue of $125,000 and net loss of $4.25M.

FINOTAUR aggregates real-time and fundamental data on IMNN to help traders and investors make informed decisions. Track IMNN in your trading journal alongside other positions for a unified view of your portfolio.